Tc-99m DTPA scans in renal allograft rejection and cyclosporine nephrotoxicity.
Renal allograft dysfunction arising from rejection or cyclosporine (CsA) nephrotoxicity can currently only be distinguished reliably by allograft biopsy. We have assessed Technetium (Tc)-99m diethylamine pentacetic acid (DTPA) scanning in 30 CsA-treated patients with allograft dysfunction. Scintigrams were performed during 20 biopsy-proved episodes of rejection and during 14 episodes of CsA nephrotoxicity. These results were compared with the scintigrams of 15 allografts showing stable function. Quantitative indices expressing allograft perfusion (flow index) and function (uptake index) derived from the DTPA scintigrams showed no significant differences between the groups of patients with rejection, CsA nephrotoxicity, or stable or improving function. Similarly, the flow and uptake indices of individual allografts obtained during periods of stable or improving function and then during episodes of dysfunction due to rejection or CsA nephrotoxicity did not significantly change. We conclude that Tc-99m DTPA scintigrams are of limited value in the management of allograft dysfunction in patients immunosuppressed with CsA.
D003524:Cyclosporins / Q000009:adverse effects*; D006084:Graft Rejection; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging / Q000187:drug effects; D016030:Kidney Transplantation; D004369:Pentetic Acid; D011877:Radionuclide Imaging; D013667:Technetium; D016284:Technetium Tc 99m Pentetate; D014184:Transplantation, Homologous
D003524:Cyclosporins; D013667:Technetium; D004369:Pentetic Acid; D016284:Technetium Tc 99m Pentetate